SRF388

Coherus Oncology, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SRF388
Sponsor	Coherus Oncology, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma (PHASE2)
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SRF388 CI brief — competitive landscape report
SRF388 updates RSS · CI watch RSS
Coherus Oncology, Inc. portfolio CI